Table 1 Description of 420 TCGA ccRCC patients
N (%) | |
|---|---|
Sex | |
Female | 137 (32.6%) |
Male | 283 (67.4%) |
Max tumor size | |
N | 376 |
Mean (SD) | 6.5 (3.5) |
Median | 5.5 |
Q1, Q3 | 4.0, 8.5 |
Range | (1.1–25.0) |
Stage | |
Missing | 44 |
Stage I | 176 (46.8%) |
Stage II | 135 (35.9%) |
Stage IV | 65 (17.3%) |
Grade | |
Missing | 44 |
G1 | 7 (1.9%) |
G2 | 156 (41.5%) |
G3 | 152 (40.4%) |
G4 | 60 (16.0%) |
GX | 1 (0.3%) |
Percent necrosis | |
Missing | 64 |
0 | 189 (53.1%) |
2 | 4 (1.1%) |
3 | 2 (0.6%) |
5 | 42 (11.8%) |
8 | 1 (0.3%) |
10 | 23 (6.5%) |
15 | 13 (3.7%) |
20 | 6 (1.7%) |
25 | 4 (1.1%) |
30 | 72 (20.2%) |
SSIGN group | |
Missing | 65 |
Low risk (0–3) | 159 (44.8%) |
Intermediate risk (4–7) | 115 (32.4%) |
High risk (8+) | 81 (22.8%) |
BAP1 mutated | |
Missing | 44 |
No | 342 (91.0%) |
Yes | 34 (9.0%) |
PBRM1 mutated | |
Missing | 44 |
No | 257 (68.4%) |
Yes | 119 (31.6%) |
SETD2 mutated | |
Missing | 44 |
No | 328 (87.2%) |
Yes | 48 (12.8%) |
VHL mutated | |
Missing | 44 |
No | 226 (60.1%) |
Yes | 150 (39.9%) |
ccA/ccB expression subtype | |
Missing | 68 |
ccB | 168 (47.7%) |
ccA | 184 (52.3%) |